Share

Merck downgraded after delaying lung cancer trial results

CNBC's Meg Tirrell reports Merck shares are down after the company delays lung cancer drug trial results and withdraws a drug application in Europe.
01:41
Mon, Oct 30 201712:46 PM EDT